NCT06636864

Brief Summary

Colorectal cancer is the second most common tumor in women and the third most common tumor in men, accounting for approximately 10% of tumors diagnosed and tumor-related deaths worldwide each year. Laparoscopic resection has become the standard of colorectal cancer surgery, and its main advantages are to shorten the length of hospital stay, reduce postoperative pain, and accelerate patient recovery. However, it has been reported that about 49% of patients undergoing laparoscopic colorectal cancer surgery still have moderate to severe postoperative pain. The insertion of abdominal drainage tube will increase the degree of postoperative pain, especially when patients take deep breaths, exercise or cough, which will increase the demand for postoperative opioids and reduce the quality of postoperative recovery. How to further reduce the postoperative pain of patients, reduce the dosage of opioids, shorten the length of hospital stay, promote the rapid recovery of patients and improve patient satisfaction are our concerns. Intrathecal morphine can provide a good analgesic effect on visceral pain. At present, intrathecal morphine has become a new method of postoperative analgesia, which is used in thoracic, abdominal and obstetrics and gynecology operations. The objective of this study was to investigate the effect of intrathecal morphine on the quality of recovery after laparoscopic colon cancer surgery.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
252

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 8, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 15, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

October 15, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2025

Completed
Last Updated

September 25, 2025

Status Verified

December 1, 2024

Enrollment Period

1 year

First QC Date

October 8, 2024

Last Update Submit

September 20, 2025

Conditions

Keywords

Laparoscopic colorectal cancer surgeryQoR-15Intrathecal morphine

Outcome Measures

Primary Outcomes (1)

  • QoR15 score at 24 hours after surgery

    Day 1 after surgery

Secondary Outcomes (9)

  • QoR15 scores 48 and 72 hours after surgery

    Day 2and 3 after surgery

  • Morphine consumption equivalent 24, 48, 72 hours after surgery

    Day 1,2and 3 after surgery

  • Rest and cough NRS scores in PACU after surgery

    30 minutes after surgery

  • NRS scores at rest, deep breathing, activity, and cough 24, 48, and 72 hours after surgery

    Day 1,2and 3 after surgery

  • Intraoperative opioid dosage

    in surgery

  • +4 more secondary outcomes

Study Arms (2)

Intrathecal morphine group

EXPERIMENTAL

Before induction of anesthesia, the experimental group received intrathecal morphine in the lumbar segment (L3/4).For our preliminary clinical application, the intrathecal morphine was 3ug/kg

Procedure: Intrathecal morphineProcedure: TAPB

Normal saline group

ACTIVE COMPARATOR

Before anesthesia induction, the control group received intrathecal injection of normal saline.

Procedure: Intrathecal saline injectionProcedure: TAPB

Interventions

The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.

Intrathecal morphine group

After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.

Normal saline group
TAPBPROCEDURE

The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes

Intrathecal morphine groupNormal saline group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Laparoscopic colorectal cancer surgery under tracheal intubation and general anesthesia is intended
  • Agreed to use intravaginal morphine injection and bupivacaine liposomal plane block of transversal muscle after surgery
  • ASA Grade I - III
  • Over 18 years of age

You may not qualify if:

  • Preoperative accident or subjective refusal of surgery
  • Nervous system dysfunction
  • Contraindications to intraspinal anesthesia
  • Preoperative opioid use history
  • Patients with abnormal preoperative pain and pain score (NRS) \>3

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

Location

Related Publications (1)

  • Zheng L, Lu Y, Lu X, You L, Yu C, Lai J, Xu M, Xie M, Xiao Y, Lai R. Intrathecal Morphine for Enhanced Recovery After Laparoscopic Colorectal Surgery: A Randomized Clinical Trial. JAMA Surg. 2025 Dec 23:e255699. doi: 10.1001/jamasurg.2025.5699. Online ahead of print.

MeSH Terms

Interventions

1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

October 8, 2024

First Posted

October 15, 2024

Study Start

October 15, 2024

Primary Completion

October 30, 2025

Study Completion

October 30, 2025

Last Updated

September 25, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations